These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30704764)

  • 1. Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study.
    Eghbali A; Khalilpour A; Taherahmadi H; Bagheri B
    Therapie; 2019 Oct; 74(5):507-512. PubMed ID: 30704764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major.
    Eghbali A; Kazemi H; Taherahmadi H; Ghandi Y; Rafiei M; Bagheri B
    Eur J Haematol; 2017 Dec; 99(6):577-581. PubMed ID: 28960482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
    Eghbali A; Shokri P; Afzal RR; Bagheri B
    Transfus Apher Sci; 2019 Aug; 58(4):429-433. PubMed ID: 31229401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S; Jain P; Sharma S; Narang M
    Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
    Maggio A; D'Amico G; Morabito A; Capra M; Ciaccio C; Cianciulli P; Di Gregorio F; Garozzo G; Malizia R; Magnano C; Mangiagli A; Quarta G; Rizzo M; D'Ascola DG; Rizzo A; Midiri M
    Blood Cells Mol Dis; 2002; 28(2):196-208. PubMed ID: 12064916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
    Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
    Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
    Perifanis V; Christoforidis A; Vlachaki E; Tsatra I; Spanos G; Athanassiou-Metaxa M
    Int J Hematol; 2007 Dec; 86(5):385-9. PubMed ID: 18192103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration in nontransfusion beta-thalassemia intermediate patients: A contemporary issue.
    Karimi M; Amirmoezi F; Haghpanah S; Ostad S; Lotfi M; Sefidbakht S; Rezaian S
    Pediatr Hematol Oncol; 2017 Aug; 34(5):292-297. PubMed ID: 29190176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
    Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.